The long-term goal of this research is to determine the genetic, cellular, and immune-mediated mechanisms associated with BCG therapy to augment current treatments, design novel therapies, and better risk stratify patients and Veterans with bladder cancer. This proposal leverages the resources of the randomized, phase III trial from the Southwest Oncology Group 1602 (S1602) involving over 900 patients treated with BCG.
|Effective start/end date||7/1/18 → 6/30/21|
- U.S. Army Medical Research and Materiel Command (W81XWH1810257)
Urinary Bladder Neoplasms